Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127360402 | 12736040 | 2 | F | 20160218 | 20160908 | 20160912 | 20160915 | EXP | FR-PFIZER INC-2016418209 | PFIZER | 54.00 | YR | F | Y | 44.00000 | KG | 20160915 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127360402 | 12736040 | 1 | PS | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | Intravenous drip | 2 MG, (SECOND CYCLE) | 71484 | 2 | MG | SOLUTION FOR INJECTION | |||||||
| 127360402 | 12736040 | 2 | SS | METHOTREXATE BIODIM | METHOTREXATE | 1 | Intrathecal | 15 MG, (SECOND CYCLE) | 0 | 15 | MG | ||||||||
| 127360402 | 12736040 | 3 | SS | MABTHERA | RITUXIMAB | 1 | Subcutaneous | 1400 MG, (SECOND CYCLE) | 0 | 1400 | MG | ||||||||
| 127360402 | 12736040 | 4 | SS | DOXORUBICIN TEVA | DOXORUBICIN | 1 | Intravenous drip | 75 MG, (SECOND CYCLE) | 0 | 75 | MG | ||||||||
| 127360402 | 12736040 | 5 | SS | ENDOXAN | CYCLOPHOSPHAMIDE | 1 | Intravenous drip | 1120 MG, (SECOND CYCLE) | 0 | 1120 | MG | ||||||||
| 127360402 | 12736040 | 6 | SS | CORTANCYL | PREDNISONE | 1 | Oral | 100 MG, UNK | 0 | 100 | MG | ||||||||
| 127360402 | 12736040 | 7 | SS | METHYLPREDNISOLONE MYLAN | METHYLPREDNISOLONE | 1 | Intravenous drip | 77.4 MG, UNK | 0 | 77.4 | MG | ||||||||
| 127360402 | 12736040 | 8 | C | NEULASTA | PEGFILGRASTIM | 1 | UNK | 0 | |||||||||||
| 127360402 | 12736040 | 9 | C | POLARAMINE | DEXCHLORPHENIRAMINE MALEATE | 1 | Intravenous bolus | 5 MG, UNK | 0 | 5 | MG | ||||||||
| 127360402 | 12736040 | 10 | C | PARACETAMOL | ACETAMINOPHEN | 1 | Intravenous drip | 500 MG, UNK | 0 | 500 | MG | ||||||||
| 127360402 | 12736040 | 11 | C | ONDANSETRON ACCORD | ONDANSETRON | 1 | Intravenous drip | 8 MG, UNK | 0 | 8 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127360402 | 12736040 | 1 | B-cell lymphoma |
| 127360402 | 12736040 | 2 | B-cell lymphoma |
| 127360402 | 12736040 | 3 | B-cell lymphoma |
| 127360402 | 12736040 | 4 | B-cell lymphoma |
| 127360402 | 12736040 | 5 | B-cell lymphoma |
| 127360402 | 12736040 | 6 | B-cell lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127360402 | 12736040 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127360402 | 12736040 | Agranulocytosis | |
| 127360402 | 12736040 | Lung disorder | |
| 127360402 | 12736040 | Pyrexia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127360402 | 12736040 | 1 | 20160212 | 0 | ||
| 127360402 | 12736040 | 2 | 20160212 | 0 | ||
| 127360402 | 12736040 | 3 | 20160212 | 0 | ||
| 127360402 | 12736040 | 4 | 20160212 | 0 | ||
| 127360402 | 12736040 | 5 | 20160212 | 0 | ||
| 127360402 | 12736040 | 6 | 20160213 | 20160216 | 0 | |
| 127360402 | 12736040 | 7 | 20160212 | 0 | ||
| 127360402 | 12736040 | 8 | 20160214 | 0 | ||
| 127360402 | 12736040 | 9 | 20160212 | 0 | ||
| 127360402 | 12736040 | 10 | 20160212 | 0 | ||
| 127360402 | 12736040 | 11 | 20160212 | 0 |